- INSM +121% on the announcement that inhalable amikacin was successful in late-stage study.
- APOP +31% on announcement that the FDA has designated ApoGraft an Orphan Drug for the prevention of acute and chronic graft versus host disease (GvHD) in transplant patients.
- BLPH +14% announced positive top line data from a Phase 2 clinical trial evaluating INOpulse in patients with Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease.
- BCRX +11% as HAE candidate BCX7353 successful in mid-stage study.
- ORMP +11% on successful meeting with FDA for oral insulin.
- SGYP +5% on $300M debt financing.